Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HRG2010 versus controlled-release levodopa/benserazide in Parkinson's disease with motor fluctuations
CTR20243461Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRG2010(II), levodopa + benserazide in Parkinson's disease (PD), sponsored by Hengrui Therapeutics. Started Dec 2024; status: completed.
02
Drugs
HRG2010(II)levodopa + benserazide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20243461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243461.